Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01296087 · ClinicalTrials.gov registry record · Phase 2
TC-6987 for the Treatment of Mild to Moderate Asthma
A Phase 2 study of Asthma, sponsored by Targacept.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
- 20
- Study locations
NCT01296087 is a Phase 2 study of Asthma that has completed, run by Targacept. The registered enrollment target is 203 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT01296087, a Phase 2 study of Asthma, has completed, sponsored by Targacept.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to determine whether TC-6987 improves respiratory function in subjects with asthma by reducing airway hyper-responsiveness and inflammation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TC-6987
Study Locations (20)
Florida
- Avail Clinical Research LLC - DeLand
- Sarasota Clinical Research - Sarasota
- Florida Pulmonary Research Institute, Inc. - Winter Park
California
- California Allergy and Asthma Medical Group, Inc. - Los Angeles
- California Allergy & Asthma Medical Group - Palmdale
Pennsylvania
- Altoona Lung Specialists - Altoona
- Allergy & Asthma Research of New Jersey, Inc. - Philadelphia
Texas
- Pioneer Research Solutions - Houston
- Paragon Research - San Antonio
Alabama
- Clinical research Center of Alabama - Birmingham
Arizona
- Medical Research of Arizona - Scottsdale
Connecticut
- Waterbury Pulmonary Associates - Waterbury
North Carolina
- Allergy Partners of Western North Carolina - Asheville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01296087
The ClinicalTrials.gov registry entry for NCT01296087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The listed sponsor is Targacept, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01296087 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01296087 about?
NCT01296087 is a clinical study titled "TC-6987 for the Treatment of Mild to Moderate Asthma". This study is designed to determine whether TC-6987 improves respiratory function in subjects with asthma by reducing airway hyper-responsiveness and inflammation.
What is the current status of trial NCT01296087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2011-02. Estimated completion is 2012-01.
What conditions does trial NCT01296087 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01296087?
The interventions under investigation include: Placebo (DRUG), TC-6987 (DRUG).
Who is sponsoring clinical trial NCT01296087?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01296087 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.